Papers/PMID:40579315
Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis.
The journal of prevention of Alzheimer's disease2025The record
1 finding drawn from this paper, on 1 compound across 1 endpoint.
What it reported
How to read these marksWhat moved
1 finding
curcumin — increases adverse event occurrence (oral or enteral supplement)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“Meta-analysis of adverse reactions associated with curcumin indicated a statistically significant increase in adverse events compared to placebo (SMD = 2.40, 95 % CI: 1.37 to 4.21, I2 = 44.1 %) (Supplementary 4 - SFigure 3).”
Quoted verbatim from Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- adults in randomised trials of oral curcumin supplementation for cognitive ageing; secondary endpoint
Effect 2.4 standardised mean difference, 95% CI 1.37 to 4.21
Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis.2025PMID:40579315